Table 2.

List of anti-TIGIT trials registered in lung cancer

ClinicalTrials.gov identifier	Status	Tumor type	Setting	Phase	Treatment cohorts	Target	Biomarker selection
NCT04952597	Active, not recruiting	SCLC	Early stage	II	Ociperlimab + tislelizumab + chemoradiotherapy Tislelizumab + chemoradiotherapy Concurrent chemoradiotherapy	TIGIT PD-1
NCT04995523	Recruiting	NSCLC	Metastatic	I/II	AZD2936	TIGIT/PD-1 bispecific	PD-L1 positive
NCT04746924	Recruiting	NSCLC	Metastatic	III	Tislelizumab + ociperlimab Pembrolizumab Tislelizumab	TIGIT PD-1	PD-L1 ≥50%
NCT03563716	Active, not recruiting	NSCLC	Metastatic	II	Tiragolumab + atezolizumab Atezolizumab	TIGIT PD-1	PD-L1 positive
NCT04256421	Active, not recruiting	SCLC	Metastatic	III	Tiragolumab + atezolizumab + chemotherapy Atezolizumab + chemotherapy	TIGIT PD-1
NCT04294810	Recruiting	NSCLC	Metastatic	III	Tiragolumab + atezolizumab Atezolizumab	TIGIT PD-1	PD-L1 high
NCT04672356	Active, not recruiting	NSCLC and SCLC	Metastatic	I	IBI939 + sintilimab	TIGIT PD-1
NCT04791839	Recruiting	NSCLC	Metastatic	II	Zimberelimab + domvanalimab + etrumadenant	PD-1 TIGIT A2aR/A2bR	PD-L1 positive
NCT04672369	Active, not recruiting	NSCLC	Metastatic	I	IBI939 + sintilimab Sintilimab	TIGIT PD-1
NCT04262856	Recruiting	NSCLC	Metastatic	II	Zimberelimab Zimberelimab + domvanalimab Zimberelimab + domvanalimab + etrumadenant	PD-1 TIGIT A2aR/A2bR	PD-L1 high
NCT04736173	Recruiting	NSCLC	Metastatic	III	Chemotherapy Zimberelimab Zimberelimab + AB154	PD-1 TIGIT	PD-L1 positive
NCT05014815	Recruiting	NSCLC	Metastatic	II	Ociperlimab + tislelizumab + chemotherapy Tislelizumab + chemotherapy	TIGIT PD-1
NCT04513925	Recruiting	NSCLC	Locally advanced	III	Tiragolumab + atezolizumab Durvalumab	TIGIT PD-1

NSCLC, non-small-cell lung cancer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; SCLC, small-cell lung cancer; TIGIT, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains.